1. Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Exp Rev Cardiovasc Ther 2004; 2: 829-835.

2. Khawaja Z, Wilcox CS. An overview of candesartan in clinical practice. Expert Rev Cardiovasc Ther 2011; 9: 975-982.

3. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253- 1287.

4. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62: 787-816.

5. Porta M, Hainer JW, Jansson SO i wsp. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia 2011; 54: 1298-1303.

6. Schaefer F, van de Walle J, Zurowska A i wsp. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 2010; 28: 1083-1090.

7. Trachtman H, Hainer JW, Sugg J i wsp., Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743-750.

8. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vascular Health and Risk Management 2011; 7: 749-759.

9. Wald DS, Law M, Morris JK i wsp. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300.

10. Yasuno S, Fujimoto A, Nakagawa Y i wsp. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther 2012; 10: 577-583.

11. McInnes GT, O’Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-S80.

12. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A i wsp. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001; 10: 43-51.

13. Bakris G, Gradman A, Reif M i wsp. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16-21.

14. Vidt DG, White WB, Ridley E i wsp. A forced titration study of anithypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475-480.

15. Zheng Z, Shi H, Jia J i wsp. A systematic review and meta- analysis of candesartan and losartan in the management of essential hypertension. J of the Renin-Angiotensin- Aldosterone Syst 2011; 12: 365-374.

16. Ozaki N, Nomura Y, Sobajima H i wsp. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med 2010; 21: 236-239.

17. Kloner RA, Weinberger M, Poole JL i wsp. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727-731.

18. Eguchi K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol 2003; 92: 621-624.

19. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Invest 2009; 29: 293-304.

20. Bönner G. Antihypertensive efficacy and tolerability of candesartan- hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press 2008; 17(Suppl. 2): 22-30.

21. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-Study. Clin Drug Invest 2000; 19: 239-246.

22. Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004; 20: 597-602.

23. MacGregor GA, Viskoper JR, Antonios TFT i wsp. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. Hypertension 2000; 36: 454-460.

24. Lindholm LH, Persson M, Alaupovic P. i wsp. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.

25. Ogihara T, Nakao K, Fukui T. i wsp. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 2008; 51: 393-398.

26. Cuspidi C, Muiesan ML, Valagussa L. i wsp. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.

27. Barrios V, Calderón A, Escobar C. i wsp. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens 2007; 25: 1967-1973.

28. Papademetriou V, Farsang C, Elmfeldt D. i wsp. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175-1180.

29. Zanchetti A, Elmfeldt D. Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE) – a review. Blood Press 2006; 15: 71-79.

30. Hajjar I, Hart M, Chen Y-L i wsp. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 2012; 172: 442-444. 31. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood- pressure-related disease, 2001. Lancet 2008; 371: 1513-1518.

32. Julius S, Nesbitt SD, Egan BM i wsp. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med 2006; 354: 1685-1697.

33. McMurray JJ, Ostergren J, Swedberg K. i wsp. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.

34. Granger CB, McMurray JJ, Yusuf S i wsp.. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.

35. Yusuf S, Pfeffer MA, Swedberg K i wsp. Effects of candesartan in patients with chronic heart failure and preserved left- ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777-781.

36. Pfeffer MA, Swedberg K, Granger CB i wsp. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet 2003; 362: 759-766.

37. O’Meara E, Solomon S, McMurray J i wsp. Effect of candesartan on New York Heart Association functional class Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004; 25: 920-1926.

38. Riegger GAJ, Bouzo H, Petr P i wsp. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-2230.

39. McKelvie RS, Yusuf S, Pericak D i wsp. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.

40. McMurray JJV, Adamopoulos S, Anker SD i wsp. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847.

41. Kasanuki H, Hagiwara N, Hosoda S i wsp. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker- based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203-12.

42. Yamaguchi J, Hagiwara N, Ogawa H i wsp., HIJ-CREATE Investigators. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Am J Cardiol 2010; 106: 819-824.

43. Koyanagi R, Hagiwara N, Yamaguchi J i wsp. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: A subanalysis of the HIJ-CREATE study. J Cardiol 2013; 62: 217-223.

44. Ducharme A, Swedberg K, Pfeffer MA i wsp. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J 2006; 151: 86-92.

45. Tveit A, Grundvold I, Olufsen M i wsp. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007; 120: 85-91.

46. Yamashita T, Inoue H, Okumura K i wsp. Randomized trial of angiotensin II-receptor blocker vs dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13: 473-479.

47. Schrader J, Luders S, Kuschewski A i wsp. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703.

48. Sandset EC, Bath PM, Boysen G i wsp. The angiotensinreceptor blocker candesartan for treatment of acute stroke (SCAST), a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377: 741-750.

49. Grassi G, Seravalle G, Dell’Oro R i wsp. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS Study. J Hypertens 2003; 21: 1761-1769.

50. Bosh J, Yusuf S, Gerdtein H i wsp. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551- 1562.

51. McMurray JJ, Holman RR, Haffner SM i wsp. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-90.

52. Bilous R, Chaturvedi N, Sjolie AK i wsp. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11-20.

53. Sjolie AK. Klein R, Porta M i wsp. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2), a randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393.

54. Chaturvedi N, Porta M, Klein R i wsp. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECTProtect 1) of retinopathy in Type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.

55. Mogensen C, Neldam S, Tikkanen I i wsp. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non- insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.

56. Kincaid-Smith P, Fairley K, Packham D i wsp. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.

57. Tamura Y, Kosuga M, Yamashita M i wsp. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease. Clin Exp Nephrol 2008; 12: 256-263.

58. Tronvik E, Stovner LJ, Helde G i wsp. Prophylactic treatment of migraine with an angiotension II receptor blocker: a randomized controlled trial. JAMA 2003; 289: 65-69.

59. Mancia G, Fagard R, Narkiewicz K i wsp. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2159-2219.

60. Widecka K, Grodzicki T, Narkiewicz K i wsp. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok: wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadc Tętn 2011; 15: 211-235.

61. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002; 11: 293-301.

62. Yusuf S, Teo K, Anderson C i wsp. Effects of the angiotensin- receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183.

63. Yusuf S, Diener H, Sacco RL i wsp. Telmisartan to prevent recurrent stroke and cardiovascular events (PRoFESS). N Engl J Med 2008; 359: 1225-1237.